Why would the FDA make such an outrageous decision to enter into an unprecedented agreement to monitor post-marketing drug surveillance with a private company run by ex-pharmaceutical executives? The FDA would be better off looking at its FAERS data. If they did, they would see drug signals that they have ignored, especially for FQ's.
Dr. Linda Martin, Dr. Alan Redd, David Melvin, and John Fratti submitted an abstract for the UMDF Symposium on behalf of the FQ community. We are pleased to announce that, after being peer-reviewed by the UMDF Abstract Review Committee, their abstract was selected as a poster for the Symposium.
"The legal and Industry Guidance bars are not too high. The problem is that the FDA has failed to do its job regarding Fluoroquinolone antibiotic safety.", Dr. Charles Bennett, PharmedOut 2015
On June 10th, 2015 representatives from the Fluoroquinolone community met with Senate Staffers at the Dirksen Senate Building in Washington, D.C. to ensure pressure is maintained on the FDA in regards to updated warnings.
“You can’t do what I do and think the drug companies don’t notice you.” With the media scrutiny and the Citizen Petitions filed over the last year you can bet that Bennett has gotten the attention of some very powerful entities; entities that are going to push back in an effort to silence or undermine our message.
